Celiac disease: Prevention and treatment

Journal of Clinical Gastroenterology

Volumn 44, Issue 1, 2010, Pages 4-8

  Selimoǧlu, Mukadder Ayşe ^a   Karabiber, Hamza ^a  

^a Inö Nü University   (Turkey)

Author keywords

Celiac disease; Prevention; Treatment

Indexed keywords

AT 1001; CYSTAMINE; CYTOKINE ANTIBODY; ENDOPROLYL PEPTIDASE; ENDOPROTEASE B 2; GASTROINTESTINAL AGENT; GLIADIN; GLUTAMINYLGLUTAMINYLPROLYLGLUTAMINYLASPARTYLALANYLVALYLGLUTAMINYLPROLYL PHENYLALANINE; GLUTEN; INTERLEUKIN 15 ANTIBODY; ISOXAZOLE DERIVATIVE; KCC 009; LEUKOCYTE ANTIGEN; PEPTIDASE; PEPTIDE DERIVATIVE; PLACEBO; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; PROTEINASE; UNCLASSIFIED DRUG;

BABY FOOD; BREAST FEEDING; CELIAC DISEASE; CLINICAL TRIAL; COMPETITIVE INHIBITION; DIETARY INTAKE; DRUG MECHANISM; ENZYME REPLACEMENT; GLUTEN FREE DIET; HIGH RISK INFANT; HUMAN; INCIDENCE; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANIMALS; BREAST FEEDING; CELIAC DISEASE; DIET, GLUTEN-FREE; ENZYMES; GLIADIN; GLUTENS; HLA ANTIGENS; HUMANS; INFANT; INTESTINES; TRANSGLUTAMINASES;

EID: 75149197424     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181b7ead2     Document Type: Review

References (59)

1. Troncone R, Ivarsson A, Szajewska H, et al. Review article: future research on coeliac disease-a position report from the European multistakeholder platform on coeliac disease (CDEUSSA). Aliment Pharmacol Ther. 2008;27:1030-1043.
2. Farrell RJ, Kelly CP. Celiac sprue. New Engl J Med. 2002;346: 180-188.
3. Fasano A. Clinical presentation of celiac disease in the pediatric population. Gastroenterology. 2005;128:S68-S73.
4. Ivarsson A, Persson LA, Nyström L, et al. Epidemic of coeliac disease in Swedish children. Acta Paediatr. 2000;89:165-171.
5. Andersen DH, Di Sant'Agnese PA. Idiopathic celiac disease: I. Mode of onset and diagnosis. Pediatrics. 1953;11:207-222.
6. Greco L, Mayer M, Grimaldi M, et al. The effect of early feeding on the onset of symptoms in celiac disease. J Pediatr Gastroenterol Nutr. 1985;4:52-55.
7. Mäki M, Kallonen K, Lähdeaho ML, et al. Changing pattern of childhood coeliac disease in Finland. Acta Paediatr Scand. 1988;77:408-412.
8. Auricchio S, Follo D, de Ritis G, et al. Does breast feeding protect against the development of clinical symptoms of celiac disease in children? J Pediatr Gastroenterol Nutr. 1983;2: 428-433.
9. Peters U, Schneeweiss S, Trautwein EA, et al. A case-control study of the effect of infant feeding on celiac disease. Ann Nutr Metab. 2001;45:135-142.
10. Fälth-Magnusson K, Franzén L, Jansson G, et al. Infant feeding history shows distinct differences between Swedish celiac and reference children. Pediatr Allergy Immunol. 1996;7:1-5.
11. Ivarsson A, Hernell O, Stenlund H, et al. Breast-feeding protects against celiac disease. Am J Clin Nutr. 2002;75:914-921.
12. Akobeng AK, Ramanan AV, Buchan I, et al. Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis of observational studies. Arch Dis Child. 2006;91:39-43.
13. Akobeng AK, Heler RF. Assessing the population impact of low rates of breast feeding on asthma, coeliac disease and obesity: the use of a new statistical method. Arch Dis Child. 2007;92:483-485.
14. D'Amico MA, Holmes J, Stavropoulos SN, et al. Presentation of pediatric celiac disease in the United States: prominent effect of breastfeeding. Clin Pediatr (Phila). 2005;44:249-258.
15. Guandalini S. The influence of gluten: weaning recommendations for healthy children and children at risk for celiac disease. Nestle Nutr Workshop Ser Pediatr Program. 2007;60: 139-151.
16. Juto P, Meeuwisse G, Mincheva-Nilsson L. Why has coeliac disease increased in Swedish children? Lancet. 1994;343: 1372.
17. Mitt K, Uibo O. Low cereal intake in Estonian infants: the possible explanation for the low frequency of coeliac disease in Estonia. Eur J Clin Nutr. 1998;52:85-88.
18. Weile B, Krasilnikoff PA. Low incidence rates by birth of symptomatic coeliac disease in a Danish population of children. Acta Paediatr. 1992;81:394-398.
19. Norris JM, Barriga K, Hoffenberg EJ, et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA. 2005;293: 2343-2351.
20. Ivarsson A, Hernell O, Nystrom L, et al. Children born in the summer have an increased risk for coeliac disease. J Epidemiol Community Health. 2003;57:36-39.
21. Kagnoff MF, Austin RK, Hubert JJ, et al. Possible role for a human adenovirus in the pathogenesis of celiac disease. J Exp Med. 1984;160:1544-1557.
22. Stene LC, Honeyman MC, Hoffenberg EJ, et al. Rotavirus infection frequency and risk of celiac disease in early childhood: a longitudinal study. Am J Gastroenterol. 2006;101: 2333-2340.
23. Troncone R, Auricchio S. Rotavirus and celiac disease: clues to the pathogenesis and perspectives on prevention. J Pediatr Gastroenterol Nutr. 2007;44:527-528.
24. Guandalini S, Gupta P. Celiac disease: a diagnostic challenge with many facets. Clin Appl Immunol Rev. 2002;2:293-305.
25. Niewinski MM. Advances in celiac disease and gluten-free diet. J Am Diet Assoc. 2008;108:661-672.
26. Catassi C, Fabiani E, Iacono G, et al. A prospective, doubleblind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007;85:160-166.
27. Collin P, Mäki M, Kaukinen K. It is the compliance, not milligrams of gluten, that is essential in the treatment of celiac disease. Nutr Rev. 2004;62:490.
28. Collin P, Mäki M, Kaukinen K. Safe gluten threshold for patients with celiac disease: some patients are more tolerant than others. Am J Clin Nutr. 2007;86:260.
29. Briani C, Samaroo D, Alaedini A. celiac disease: from gluten to autoimmunity. Autoimmun Rev. 2008;7:644-650.
30. Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40:1-19.
31. Ludvigsson JF, Reutfors J, Osby U, et al. Coeliac disease and risk of mood disorders-a general population-based cohort study. J Affect Disord. 2007;99:117-126. (Pubitemid 46275025)
32. Sadiq Butt M, Tahir-Nadeem M, Khan MK, et al. Oat: unique among the cereals. Eur J Nutr. 2008;47:68-79.
33. Thompson T. Gluten contamination of commercial oat products in the United States. N Engl J Med. 2004;351:2021-2022.
34. Janatuinen EK, Kemppainen TA, Julkunen RJ, et al. No harm from five year ingestion of oats in coeliac disease. Gut. 2002; 50:332-335.
35. Holm K, Maki M, Vuolteenaho N, et al. Oats in the treatment of childhood coeliac disease: a 2-year controlled trial and a longterm clinical follow-up study. Aliment Pharmacol Ther. 2006;23:1463-1472.
36. West J, Logan RF, Card TR, et al. Risk of vascular disease in adults with diagnosed coeliac disease: a population-based study. Aliment Pharmacol Ther. 2004;20:73-79. (Pubitemid 38938721)
37. Cerf-Bensussan N, Matysiak-Budnik T, Cellier C, et al. Oral proteases: a new approach to managing coeliac disease. Gut. 2007;56:157-160.
38. Dickey W, Kearney N. Overweight in celiac disease: prevalence, clinical characteristics, and effect of a gluten-free diet. Am J Gastroenterol. 2006;101:2356-2359.
39. Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297:2218-2220.
40. Shan L, Qiao SW, Arentz-Hansen H, et al. Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. J Proteome Res. 2005;4: 1732-1741.
41. Stepniak D, Spaenij-Dekking L, Mitea C, et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol. 2006;291:G621-G629.
42. Pyle GG, Paaso B, Anderson BE, et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin Gastroenterol Hepatol. 2005;3:687-694.
43. Mitea C, Havenaar R, Drijfhout JW, et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut. 2008;57:25-32.
44. Gass J, Vora H, Bethune MT, et al. Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat. J Pharmacol Exp Ther. 2006;318:1178-1186.
45. Gobbetti M, Giuseppe Rizzello C, Di Cagno R, et al. Sourdough lactobacilli and celiac disease. Food Microbiol. 2007;24:187-196.
46. Di Cagno R, De Angelis M, Auricchio S, et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol. 2004;70:1088-1096.
47. Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, et al. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology. 2005;129:797-806.
48. Spaenij-Dekking L, Kooy-Winkelaar Y, Koning F. The Ethiopian cereal tef in celiac disease. N Engl J Med. 2005; 353:1748-1749.
49. Silano M, Di Benedetto R, Trecca A, et al. A decapeptide from durum wheat prevents celiac peripheral blood lymphocytes from activation by gliadin peptides. Pediatr Res. 2007; 61:67-71.
50. Xia J, Siegel M, Bergseng E, et al. Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin. J Am Chem Soc. 2006;128:1859-1867.
51. Xia J, Bergseng E, Fleckenstein B, et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg Med Chem. 2007;15: 6565-6573.
52. Sollid LM, Khosla C. Future therapeutic options for celiac disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:140-147.
53. Molberg O, McAdam S, Lundin KE, et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol. 2001; 31:1317-1323.
54. Choi K, Siegel M, Piper JL, et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol. 2005;12:469-475.
55. Mention JJ, Ben Ahmed M, Begue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003;125:730-745.
56. Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000;355:1518-1519.
57. Smecuol E, Sugai E, Niveloni S, et al. Permeability, zonulin production, and enteropathy in dermatitis herpetiformis. Clin Gastroenterol Hepatol. 2005;3:335-341.
58. Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007;26: 757-766.
59. Drago S, El Asmar R, Di Pierro M, et al. Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol. 2006; 41:408-419.